Title: Boards that cannot question AI claims need an independent questioner — Straven’s room in the boardroom.
As directors of healthcare, insurance, and financial services organisations in Canada and the UK, you’re faced with a growing threat to your operations: untested artificial intelligence (AI) solutions. Vendors promise more than they deliver, and regulators scrutinise every decision. In this environment, boards must question AI claims before committing resources.
What is happening? Many vendors claim their AI products can revolutionise healthcare by improving patient outcomes, reduce insurance claims processing time, or identify high-risk financial transactions. However, organisations are now required to demonstrate the capability, governance, and legal compliance of these solutions. This demands a deeper understanding of AI capabilities than ever before.
Why it demands action now: Your exposure is twofold. Firstly, untested AI systems may not live up to their promises, leading to reputational damage, lost business, or even patient harm. Secondly, regulatory bodies will hold you accountable for any errors the AI makes. Boards are responsible for ensuring governance and legal compliance are in place.
The action: A prudent organisation must take a strategic approach. First, it should conduct thorough research on vendors’ claims. Next, it needs to assess the technical capabilities of the solution against its real operations and people. Finally, it should consider independent validation from experts who can provide an unbiased view.
How Straven & Co helps: The company provides independent AI validation by testing proposed solutions against clients’ actual operations, people, governance obligations, and legal and regulatory exposure. This results in a plain verdict: proceed, proceed with conditions, or do not. By offering no product to sell and earning nothing from recommending more, Straven’s judgment can be trusted.
Straven & Co examines AI decisions before they are acted on: stravenandco.com